Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958265 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase 3 study of Atypical Hemolytic-Uremic Syndrome, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT04958265 is a Phase 3 study of Atypical Hemolytic-Uremic Syndrome that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 41 participants, below the 1,039-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04958265, a Phase 3 study of Atypical Hemolytic-Uremic Syndrome, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Conditions Studied
Interventions
- DRUG Crovalimab
Study Locations (20)
Other
- UZ Gent - Ghent
- UZ Leuven Gasthuisberg - Leuven
- Peking University First Hospital - Beijing
- Beijing Children's Hospital, Capital Medical University - Beijing
- The children's hospital , Zhejiang university school of medicine - Hangzhou
- Hôpital Arnaud de Villeneuve - Montpellier
- Gh Necker Enfants Malades - Paris
- Aichi Children?s Health and Medical Center - Aichi
- Chiba Children's Hospital - Chibashi, Chibaken
- Hospital de Especialidades Puerta de Hierro S.A de C.V. - Zapopan
Colorado
- Children's Hospital Colorado - Aurora
Nebraska
- University of Nebraska - Omaha
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- UT Health Science Center - San Antonio
São Paulo
- Inst. Da Criança- Faculdade de Medicina Usp - São Paulo
Quebec
- CHU Sainte-Justine - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2029-05-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958265
The ClinicalTrials.gov registry entry for NCT04958265 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,039-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atypical Hemolytic-Uremic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Crovalimab is the first listed.
NCT04958265 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Colorado, Nebraska.
Frequently Asked Questions
What is clinical trial NCT04958265 about?
NCT04958265 is a clinical study titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)". This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
What is the current status of trial NCT04958265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2021-11-17. Estimated completion is 2029-05-19.
What conditions does trial NCT04958265 study?
This clinical trial studies the following conditions: Atypical Hemolytic-Uremic Syndrome.
What interventions are being tested in trial NCT04958265?
The interventions under investigation include: Crovalimab (DRUG).
Who is sponsoring clinical trial NCT04958265?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04958265 being conducted?
This trial has 20 study locations across Colorado, Nebraska, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Hemolytic-Uremic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
-
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.